Who We Are
As the world's leading provider of generic drugs, Teva Pharmaceuticals understands the importance of making safe, quality medications accessible—and affordable.
At Teva, we continually evaluate and pursue growth opportunities that advance our goal of being a stronger, more diversified organization with the scale and resources to drive value across our business today and in the future. With the acquisition of Actavis Generics, our combined company will offer the richest product pipeline in the generic industry and will continue to lead the way with complementary technologies and product portfolios, offering more differentiated and durable products than any other generic company of this scale. Learn more about the acquisition.
One in five of the 3.78 billion generic prescriptions written in the United States is filled with a Teva product.1 This makes better healthcare accessible to patients. Teva helped contribute to the $254 billon dollars in savings in U.S. healthcare by providing affordable generic drugs!2
Teva's extensive U.S. operations are headquartered outside of Philadelphia, Pa., and include more than 9,500 employees in more than 45 facilities across the United States and its Territories.3 Our generic products include a wide variety of therapeutic options, ranging from cardiovascular, anti-infective, central nervous system, anti-inflammatory, oncolytic, anti-diabetic, analgesic, dermatologic, respiratory, and women's health, with dosage forms including tablets, capsules, injectables, creams, ointments, inhalants, solutions, and suspensions.
Teva Pharmaceuticals USA is a wholly owned subsidiary of Israeli-based Teva Pharmaceutical Industries Ltd., the global leader in generics and one of the top 10 pharmaceutical companies in the world.
1. IMS Health NPA Data as of MAT June 2016
2. Generic Pharmaceutical Association. Generic Drug Savings in the U.S. Seventh Annual Edition: 2015. http://www.gphaonline.org/media/wysiwyg/PDF/GPhA_Savings_Report_2015.pdf. Accessed July 19, 2016
3. Internal Data on File